Recently, we and others have shown that the interaction between envelope specific antibodies and primary human immunodeficiency virus type 1 (HIV-1) isolates may result in either inhibition or enhancement of virus entry. The outcome proved to be determined by the virus isolate rather than by the specificity of the antiserum used. To study the mechanism underlying this phenomenon, a series of HIV-1 envelope glycoproteins from closely related primary virus isolates of different syncytium inducing phenotypes, together with chimeras of these proteins, were tested in an envelope transcomplementation assay for their sensitivity to either antibody mediated inhibition or enhancement of HIV-1 entry. Based on the observation that, in contrast to the inhibition of HIV-1 entry, antibody mediated enhancement was not temperature de-
Introduction
The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein complex of T cell line adapted (TCLA) strains has been shown to mediate virus entry by a pHindependent mechanism which is initiated by a high affinity interaction between the surface glycoprotein (SU, gp120) and the cellular receptor CD4 (Stein et al., 1987) . Apart from this high affinity interaction, a lower affinity interaction with a second receptor is required for HIV-1 entry (Maddon et al., 1986) . These interactions of HIV-1 glycoproteins with cell surface molecules lead to conformational changes within the HIV-1 glycoprotein complex and shedding of gp120, which eventually results in the fusion of viral and cellular membranes (Allan, 1991 ; Moore et al., 1991) . Both soluble CD4 (sCD4) and antibodies directed against the envelope glycoproteins may interfere with this process of virus entry in several ways. pendent and could not be mediated by F(ab) fragments, we concluded that the mechanisms underlying these phenomena are different and that antibody mediated enhancement of HIV-1 entry is largely if not exclusively mediated by HIV-1 glycoprotein cross-linking. The susceptibility of the envelope glycoprotein chimeric viruses to neutralization or enhancement of infectivity proved to be primarily determined by the configuration of the V3 loop, and the affinity of the antibodies to monomeric HIV-1 gp160 molecules, proved to be of quantitative importance only. One human monoclonal antibody directed against gp41 (IAM 2F5) inhibited entry of all the viruses studied, irrespective of their phenotype, and directly proportional to its affinity to monomeric HIV-1 gp160.
They may block the interaction between gp120 and the cell surface molecules, induce conformational changes which disable the envelope glycoprotein complex from further functionality, or induce premature shedding of gp120 (Clapham et al., 1989 ; Moore et al., 1990 ; Orloff et al., 1993 ; Poignard et al., 1996) .
It has become clear that the glycoprotein complex of HIV-1 isolates that have only been propagated in peripheral blood mononuclear cell (PBMC) cultures differs from that of TCLA HIV-1 strains in several respects. The so-called primary HIV-1 isolates are less susceptible to virus neutralization by sCD4 and antibodies directed to the V3 loop or the CD4 binding domain (CD4 bd) (Moore et al., 1995 ; Schutten et al., 1996) . Furthermore, as was also shown for HIV-2 and simian immunodeficiency virus (SIV) strain agm, primary HIV-1 isolates do not readily shed gp120 upon binding to sCD4 (Allan, 1991 ; Moore et al., 1992) . We and others have recently shown that sCD4 may enhance primary HIV-1 envelope glycoprotein mediated entry (Schutten et al., 1995 a ; Sullivan et al., 1995) , a phenomenon that has also been described for HIV-2 and SIVagm strains (Clapham et al., 1992 ; Werner et al., 1990) . This enhancement of HIV-1 envelope glycoprotein mediated entry is also mediated by polyclonal HIV-1 specific antibody (HIVIG) and by HIV-1 gp120 specific human monoclonal antibodies (HuMAbs) directed against either the V3 loop or the CD4 bd. It may be speculated that antibody mediated enhancement (AME) is a common strategy of these closely related lentiviruses in order to escape from -or even take advantage of -virus neutralizing antibodies Kostrikis et al., 1996) . Why such a common strategy has not been identified previously may be due to a selection against AME sensitive viruses in HIV-1 isolation procedures. The use of mitogen stimulated PBMC in the absence of virus specific antibodies may be expected to favour the isolation of T cell tropic viruses (Innocenti-Francillard et al., 1994) .
In the present paper we present results of studies on the mechanism underlying AME, a phenomenon that is essentially different from the previously described Fc receptor and complement receptor mediated antibody dependent enhancement mechanisms of HIV-1 infectivity (Eaton et al., 1994 ; Robinson et al., 1990 ; Schutten et al., 1995a) . To this end a series of HIV-1 envelope glycoproteins from closely related primary HIV-1 biological clones of different in vitro biological phenotypes, together with chimeras of these proteins, were tested in an envelope trans-complementation assay (ETCA) for their sensitivity to either antibody mediated inhibition of HIV-1 entry (IE) or AME.
Methods
Human antibodies and HIV-1 envelope glycoproteins. The antibodies used in this study are the CD4 bd specific HuMAbs GP13 (Schutten et al., 1993) and IgG1-b12 (Burton et al., 1994) , the combinatorial phage display library F(ab) fragment FAB12 (Roben et al., 1994) which was used to generate IgG1-b12, V3 loop specific HuMAbs 257-D (Gorny et al., 1993) and MN215 (Schutten et al., 1995 b) , HuMAb K14 directed against a highly conserved conformational epitope on gp41 (Teeuwsen et al., 1990) and IAM 2F5, which is specific for a relatively conserved epitope on gp41 (ELDKWAS) (Muster et al., 1993) . The use of the TCLA HIV-1 envelope gene derived from the HIV-1 IIIB isolate (HXB2-D) in the envelope trans-complementation assay has been described previously (Helseth et al., 1990) . The previously described Groenink et al., 1992) HIV-1 env genes derived from primary biological HIV-1 clones from donors F 16 and F 320 from the Amsterdam cohort of seropositive individuals designated 16.1 (SI), 16.2 (SI), 16.4 (NSI), 320.2A.6 (NSI) and 320.2A.7 (SI) were used for the production of viruses expressing the respective envelope glycoproteins. The env gene from the HIV-1 biological clone 168.10 (SI) had been generated using a similar protocol (de Jong et al., 1992 ; . The generation and characterization of the SI\NSI envelope chimeras have been described in more detail by Andeweg et al. (1993) .
Affinity of the HuMAbs used for the monomeric recombinant glycoproteins. The affinity of the HuMAbs for the monomeric form of the envelope glycoproteins expressed by the chimeric HIV-1 virions used in the envelope complementation assay was determined in a previously described capture antibody ELISA (D7324, Aalto Bioreagents) (Andeweg et al., 1993 ; Moore, 1990) . In short, the primary envelope glycoproteins were expressed in COS cells (Gluzman, 1981) using a vaccinia virus expression system. Vaccinia virus infected cells were lysed with 1 % Empigen and the amount of HIV-1 glycoprotein in the cell lysate was estimated using the capture antibody ELISA. Subsequently, equal amounts of HIV-1 glycoprotein were coated and the concentration of HuMAb was determined where half maximum binding was reached in the capture antibody ELISA. This concentration was taken as the relative affinity of the HuMAb for the HIV-1 envelope glycoprotein tested.
Despite the pronounced amino acid variation in the hypervariable regions of the envelope glycoproteins, all HuMAbs showed a similar relatively high affinity for the envelope glycoproteins (Schutten et al., 1995 b, and unpublished results) . HuMAb IAM 2F5 (gp41), however, showed low affinity for the 16.4 (NSI) envelope glycoprotein and HuMAb MN215 (V3 loop) showed low affinity for all SI envelope glycoproteins (Schutten et al., 1995 b) . The low affinity of HuMAb IAM-2F5 for the F 16.4 (NSI) envelope glycoprotein may be explained by the lysine to threonine change in the 16.4 (NSI) amino acid sequence (ELDTWAS) relative to the optimal binding sequence for IAM 2F5 (ELDKWAS) (Muster et al., 1993) .
Envelope trans-complementation assay (ETCA). This was based on a previously described assay in which an envelope gene defective HIV-1 provirus encoding the bacterial CAT reporter gene was complemented for a single round of replication by the set of HIV-1 envelope genes (Helseth et al., 1990) . In the ETCA the plasmids encoding the envelope glycoproteins were co-transfected by electroporation into a CD4 − cell line (COS) (Gluzman, 1981) together with the envelope gene defective molecular clone of the HIV-1 IIIB strain. This resulted in the production of virions carrying heterologous envelope glycoproteins which may infect CD4 + cells. Cell free supernatants were collected after 3 days of culture by centrifugation and frozen at k135 mC. The amount of virus particles used for infection was adjusted by calibrating the amount of p24 antigen, as determined with a p24 ELISA kit (V5, Organon Teknika) to a standard amount of p24. The level of envelope expression was checked with the capture antibody ELISA described above. For infection the Sup T1 T cell line (Smith et al., 1984) and PBMC prestimulated for 3 days with PHA (PHA-M, Boehringer Mannheim ; 15 µg\ml) were used. Infection of Sup T1 cells (2i10'\ml) and PHA prestimulated PBMC (5i10'\ml) was routinely performed overnight at 37 mC in 1 ml RPMI 1640 (GIBCO BRL Life Technologies) with 10 % foetal calf serum, penicillin and streptomycin in the absence or presence of 15 µg HuMAb or 30 µg FAB12. To determine the temperature sensitivity of IE and AME, infection was performed at 4, 20 and 37 mC for 5 h. After infection the cells were washed and cultured for another 72 h. CAT activity, measured in c.p.m., was determined in a previously described CAT assay using a two phase extraction system (Seed & Sheen, 1988) . CAT activities expressed by the cells were considered to be a direct measure of the capacity of the envelope gene product to mediate virus entry. The mean value of duplicates within one experiment is given. Each antibody-virus combination was tested in at least two separate experiments yielding similar results.
Results

Antibody mediated inhibition and enhancement of entry using a set of chimeric viruses carrying primary HIV-1 glycoproteins
The efficiency of HIV-1 envelope glycoprotein mediated entry into the Sup T1 T cell line and the capacity of the respective HuMAbs at a given concentration (15 µg\ml) to BAAA Fig. 1 . Efficiency of entry into Sup T1 cells of primary and TCLA HIV-1 glycoprotein complemented chimeric virus in the absence and presence of HIV-1 envelope glycoprotein specific HuMAbs, determined in the ETCA. On the x-axis IE or AME mediated by HIV-1 envelope glycoprotein specific HuMAbs are given as the percentages of CAT activity obtained with 15 µg/ml of HuMAb relative to CAT activity obtained with the same HIV-1 envelope glycoprotein complemented virus without HuMAb. On the right CAT activities obtained with the chimeric viruses without using HuMAb are presented.
inhibit or enhance the process of entry mediated by these envelope glycoproteins was determined in the ETCA (Fig. 1) . The capacity of the HuMAbs to inhibit entry of HXB2-D envelope complemented virus was proportional to their previously reported capacity to neutralize HIV-1 strain IIIB (Burton et al., 1994 ; Gorny et al., 1993 ; Muster et al., 1993 ; Schutten et al., 1993 ; Teeuwsen et al., 1990) . HuMAb K14, which does not neutralize TCLA viruses in in vitro assays, did not influence entry mediated by any of the primary envelope glycoprotein complemented viruses. The V3 loop specific HuMAb 257-D efficiently inhibited entry (inhibition of entry 90 %) of one of the six chimeric viruses, which expressed the envelope glycoprotein derived from primary HIV-1 strain 16.2 (SI), and enhanced envelope 16.4 (NSI) mediated entry (enhancement of entry 200 %). The CD4 bd specific HuMAb GP13 inhibited envelope 16.2 (SI) mediated entry by about 50 % and enhanced envelope 16.4 (NSI) mediated entry by about fivefold. IgG1-b12, which is also directed against the CD4 bd, inhibited entry of the envelope 320.2A.6 (NSI), 16.1 (SI) and 16.2 (SI) complemented viruses and enhanced envelope 16.4 (NSI) mediated entry by about threefold. HuMAb IAM 2F5, directed against the proximal putative α-helix of gp41, inhibited entry of all the chimeric viruses into Sup T1 cells by more than 90 % with the exception of envelope 16.4 (NSI) chimeric virus, to which it displayed a much lower affinity. Entry of this chimeric virus was reduced to about 50 % by HuMAb IAM 2F5.
Inhibition and enhancement of virus entry in relation to HIV-1 envelope glycoprotein cross-linking by antibodies
IgG1-b12 and the F(ab) fragments (FAB12) which had been used to generate IgG1-b12 were used to evaluate whether IE and AME of chimeric 16.2 (SI) and 16.4 (NSI) viruses respectively, required cross-linking. IgG1-b12 and its F(ab) fragments were selected since IgG1-b12 showed broad IE activity against the primary HIV-1 envelope glycoprotein complemented viruses (Fig. 2) . The level of IE of the envelope 16.2 (SI) chimeric virus mediated by FAB12 and IgG1-b12 were of the same order of magnitude. However, enhancement of envelope 16.4 (NSI) mediated entry was only observed with IgG1-b12, whereas the F(ab) fragments of IgG1-b12 failed to enhance entry mediated by this envelope glycoprotein. Since IgG1-b12 does not bind to Sup T1 cells in FACS analysis, which is consistent with the lack of Fc receptors on Sup T1, the BAAB M. Schutten and others M. Schutten and others lack of AME by FAB12 could not be attributed to the mere absence of the Fc portion of the antibody.
Antibody mediated inhibition and enhancement of entry at different temperatures
HuMAb 257-D was selected to study the effects of different temperatures on IE and AME, since this antibody recognizes a linear epitope (IHIGPG) that is most probably less dependent on the conformation of the envelope glycoprotein (Gorny et al., 1993) . Furthermore, probably due to the high affinity of HuMAb 257-D for the recombinant glycoproteins derived from donor F 16, HuMAb 257-D completely blocked entry of envelope 16.2 (SI) chimeric virus. AME of envelope 16.4 (NSI) chimeric virus mediated by HuMAb 257-D typically resulted in levels of CAT activity which were similar to those found for envelope 16.2 (SI) chimeric virus when tested in the absence of HuMAb (Fig. 1) . At decreasing temperatures CAT activity levels declined for envelope 16.2 (SI) and envelope 16.4 (NSI) complemented viruses (Fig. 3) . This was probably due to the lower efficiency of entry at lower temperatures although limited cell death during the 5 h incubation at lower temperature was also observed. The decrease in maximum CAT activities at lower temperatures obscures the efficiency of inhibition and enhancement of entry if these are given as ratios. In Fig. 3 , in contrast to Figs 1, 2 and 4, actual CAT activity values are therefore given. To determine the efficiency of inhibition and enhancement of entry by HuMAb 257-D, CAT activity values obtained in the presence of HuMAb 257-D at a given temperature are compared with the minimum and maximum CAT activity values respectively at that given temperature. IE and AME mediated by HuMAb 257-D with envelope 16.2 (SI) and envelope 16.4 (NSI) chimeric viruses, at decreasing temperatures, were tested in parallel (Fig. 3) . The level of IE of envelope 16.2 (SI) chimeric virus proved to have decreased significantly at 20 mC (CAT activity about twice background) and even more at 4 mC (CAT activity about five times background) when compared to the complete block of entry at 37 mC (background CAT activity). In contrast, the level of AME of envelope 16.4 (NSI) chimeric virus proved not to be affected by the lower temperatures : the CAT activity values obtained with envelope 16.4 (NSI) chimeric virus at different temperatures in the presence of HuMAb 257-D were virtually identical to the values obtained with envelope 16.2 (SI) chimeric virus at the same temperature in the absence of antibody. Collectively, these results show that in contrast to the level of IE, the level of AME is not significantly influenced by decreased temperature.
Antibody mediated inhibition and enhancement of entry in a set of viruses carrying hybrid SI/NSI constructs
Using a series of HIV-1 envelope glycoproteins with different biological phenotypes, originating from one patient at one time-point, and hybrids generated from these proteins, an ETCA was carried out with a V3 loop specific (MN215) and a CD4 bd specific (GP13) HuMAb in Sup T1 cells (Fig. 4) . The ratio of the CAT activity measured in Sup T1 cells versus the CAT activity measured in PHA stimulated PBMC was taken as a measure of the relative efficiency of entry of the respective chimeric viruses into Sup T1 cells.
The sensitivity of envelope 16.2 (SI) to IE was transferred to envelope 16.1 (SI) and envelope 16.4 (NSI) proteins by the transfer of the envelope 16.2 (SI) aa 1-610 fragment (12AX and 42AX). These two constructs mediated efficient entry into Sup T1 cells, suggesting that both the efficiency of entry into Sup T1 cells and the sensitivity of the chimeric viruses to either IE or AME mediated by both HuMAbs is a trait of gp120. The transfer of the V3-V5 region of envelope 16.2 (SI) (StuI-AvrII, aa 211-610) to envelope 16.4 (NSI) (24SA), resulted in a hybrid envelope mediating a relatively high efficiency of entry into Sup T1. This exchange also changed the sensitivity of the envelope 16.4 (NSI) from AME sensitive to IE sensitive. We have previously shown that within the StuI-AvrII fragment of envelope 16.2 (SI), the V3 domain (aa 272-378, HindII-CvnI) alone proved to be sufficient to transfer the SI capacity of envelope 16.2 (SI) to an NSI background (Andeweg et al., 1993) . In line with this finding the envelope 16.2 (SI) based construct containing the 16.4 (NSI) V3 loop (42HC) showed a relatively low efficiency of entry into Sup T1 and entry mediated by this construct envelope was still significantly enhanced by both HuMAbs. These data suggest that within M. Schutten and others M. Schutten and others the 16.2 (SI) and 16.4 (NSI) HIV-1 envelope glycoproteins the V3 loop may not only determine the efficiency of Sup T1 entry but also the sensitivity to IE or AME.
However, in contrast to this observation, exchange of the 16.4 (NSI) V3 domain for the 16.1 V3 domain (14HC) failed to significantly increase the efficiency of entry into Sup T1, and also failed to change the AME phenotype of the envelope 16.4 (NSI) chimeric virus (Fig. 4) .
Discussion
Naturally occurring changes within the HIV-1 env gene contribute to the in vitro biological characteristics used to describe the phenotype of HIV-1 strains. These biological characteristics include the syncytium inducing capacity, cellular host range, replicative capacity and the ability to induce single cell lysis. In the present paper we have shown that the sensitivity of HIV-1 strains to IE or AME is also determined by naturally occurring changes in envelope regions, which directly influence the SI capacity and efficiency of virus entry.
HuMAb 257-D and HuMAb IgG1-b12 only inhibited entry mediated by a limited number of the HIV-1 envelope glycoproteins tested (one and three out of six, respectively) ( Fig. 1) , although their affinities for the monomeric HIV-1 envelope glycoproteins used proved to be within the same range. The lack of biological activity of these HuMAbs towards the other viruses suggests that they either do not bind to the oligomeric HIV-1 glycoprotein complex of these viruses or do not exert biological activity after binding. The former explanation seems consistent with our previous FACS studies using vaccinia virus expressed HIV-1 envelope glycoproteins, which showed that VN inducing sites are less well presented by oligomeric primary HIV-1 glycoprotein complexes used in the present study than by their monomeric counterparts (Sattentau et al., 1994) . However, HuMAbs directed against these sites were shown by others to bind oligomeric HIV-1 glycoprotein complexes present on primary HIV-1 infected cells (Zolla-Pazner et al., 1995) , indicating that the conformation of the HIV-1 glycoprotein complex present on HIV-1 virions may be essentially different from that of vaccinia virus expressed cell membrane associated envelope glycoproteins (Q. Sattentau, personal communications). Therefore, lack of biological activity after binding may still be a more likely explanation. This may either be due to the absence of involvement of the antibody binding site of these viruses in the process of entry, or alternatively, binding of these antibodies does not induce the changes needed to inhibit entry of these viruses. The results of the ETCA experiments with the SI\NSI hybrid constructs, presented in this study, seem to favour the explanation that the binding sites are not involved in the process of entry of these viruses. It has recently been shown that NSI and SI HIV-1 strains use different second receptor molecules during envelope mediated entry (Deng et al., 1996 ; Feng et al., 1996) . The CXCR-4 α-chemokine receptor proved to be the second receptor for SI or T cell line adapted HIV-1 strains, whereas NSI\macrophage-tropic HIV-1 strains required expression of the β-chemokine receptors CCR-2a, CCR-3 or CCR-5 for entry (Doranz et al., 1996 ; Choe et al., 1996) . Despite the fact that T cells express different α and β chemokine receptors including CCR-5, NSI HIV-1 strains replicate usually less efficiently in T cells as compared to SI HIV-1 strains (Schutten et al., 1995 a ; Sullivan et al., 1995) . The differential requirements of these HIV-1 strains for second receptor molecules proved to be determined at least in part by the configuration of the V3 loop . It may therefore be speculated that the inability of the HIV-1 envelope glycoproteins expressing the 16.4 (NSI) V3 loop to mediate entry via CXCR-4 may be overcome by adding HIV-1 gp120 specific antibodies. It should be realized that the number of amino acid differences between these closely related proteins is limited . Still, despite the high degree of homology, in particular in those regions that apparently govern syncytium induction and entry, the HIV-1 chimeric viruses differ significantly in their sensitivities to IE or AME.
The temperature dependent nature of IE (Fig. 3) suggests that the induction of conformational changes in the HIV-1 envelope glycoprotein complex after binding of the HuMAbs is essential for IE. This has also been suggested for the neutralization of TCLA HIV-1 strains by gp160 specific antibodies (Poignard et al., 1996 ; . The observation that HuMAbs with relatively low affinity to 16.4 (NSI) envelope glycoprotein induce levels of AME similar to those with high affinity (M. Schutten, unpublished) , together with the apparent temperature independent nature of AME (Fig. 3) , led us to conclude that the changes induced by antibodies and sCD4, leading to AME, have a minimal energy requirement. Furthermore, IE and AME both proved to be dependent on the concentration of antibody or sCD4 (Schutten et al., 1995 a ; Sullivan et al., 1995) : IE reached a plateau value at increasing concentrations whereas AME increased with concentration to an optimum level. Collectively, these data indicate that the mechanisms which underlie IE and AME are fundamentally different and that antibody mediated crosslinking is essential for AME. This was confirmed by the observation that FAB12 did not induce AME although its IE inducing capacity toward IE sensitive viruses was equal to that of IgG1-b12 (Fig. 2) . In this light, it is interesting to note that sCD4 exhibits the same pattern of IE and AME with the respective chimeric viruses as V3 domain specific antibodies, and sCD4 induces conformational changes within the HIV-1 glycoprotein complex similar to V3 loop specific antibodies (Poignard et al., 1996) . Furthermore, the concentration dependency of sCD4 was essentially the same as that of antibody induced AME, suggesting that cross-linking is required for sCD4 induced AME (Sullivan et al., 1995) . It is not clear, however, how sCD4, which is a monomeric structure (Malvoisin & Wild, 1994) , may cause cross-linking. We postulate that either sCD4 dimerizes with membrane associated proteins that also bind to HIV-1 gp120, or that more than one recognition site exists between gp120 and sCD4. The former explanation seems the most likely one, since only recently it was shown that a D1-D2 fragment of CD4 bound to CCR-5, which also binds to HIV-1 gp120 (Wu et al., 1996) . Since sCD4 activated HIV-1 and HIV-2 glycoprotein mediated membrane fusion has been suggested to parallel gp120-CD4 activated membrane fusion (Allan, 1991) , the high affinity interaction of HIV-1 gp120 with CD4 is probably required to establish a stable complex between the oligomeric HIV-1 glycoprotein complex and cellular CD4. This interaction then induces conformational changes allowing the gp120-CD4 complex to bind to members of the α and β chemokine receptor family Wu et al., 1996) . This complex interaction may subsequently induce conformational changes within the gp120-CD4 complex, resulting in a fusogenic state of the whole envelope-CD4 complex.
The capacity of HuMAb IAM 2F5 to inhibit entry of all the chimeric viruses tested (Fig. 1) indicates that this antibody, in contrast to the gp120 specific HuMAbs used in these studies, blocks an essential step in the process of entry of both TCLA and primary viruses. This antibody binds to the relatively conserved proximal part of a putative α-helix which is essential for HIV-1 IIIB envelope glycoprotein mediated entry. Therefore, we conclude that the site recognized by HuMAb IAM 2F5, rather than those involved in AME, may be the most suitable target for antibody mediated immune intervention.
